| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Restenosis after recanalization for Budd-Chiari syndrome: Management and long-term results of 60 patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wei Zhang, Yu-Long Tian, Qiao-Zheng Wang, Xiao-Wei Chen, Qi-Yang Li, Jin-Hang Han, Xu-Dong Chen and Ke Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ke Xu, MD, PhD, Professor, Department of Interventional Radiology, The First Affiliated Hospital of China Medical University, 155 Nanjing Bei Street, Shenyang 110001, Liaoning Province, China. kexu@vip.sina.com |
| Key Words |
Budd-Chiari syndrome; Restenosis; Long-term follow-up; Treatment strategy; ; |
| Core Tip |
This is the first study to explore the treatment strategy for restenosis in Chinese patients with Budd-Chiari syndrome after interventional therapy and evaluate the outcomes with more than 20-year follow-up. The 1-, 5-, 10-, 20- and 25-year cumulative survival rates of the 38 patients who received further treatment after restenosis were 100%, 78.3%, 78.3%, 70.5% and 70.5%, respectively; however, for the 22 patients who refused treatment, the survival rates were 72.7%, 45.9%, 30.6%, 10.2% and unavailable, respectively (P < 0.001). Regular follow-up and active treatment can result in satisfactory prognosis in Budd-Chiari syndrome patients with restenosis. |
| Publish Date |
2020-07-24 12:21 |
| Citation |
Zhang W, Tian YL, Wang QZ, Chen XW, Li QY, Han JH, Chen XD, Xu K. Restenosis after recanalization for Budd-Chiari syndrome: Management and long-term results of 60 patients. World J Clin Cases 2020; 8(14): 2930-2941 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i14/2930.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i14.2930 |
